ArticleNature medicine2018
Modeling cytokine release syndrome.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Trial
- First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.Blood advances · 2019Trial
- Recent Locoregional CAR T-Cell Trials for the Treatment of Recurrent Glioblastoma: Implications for Neuro-Oncology Practice.CNS drugs · 2026Review
- Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.Blood cancer journal · 2025Article
- CAR-T State of the Art and Future Challenges, A Regulatory Perspective.International journal of molecular sciences · 2023Review
- Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.Blood advances · 2023Article
- Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling.Frontiers in immunology · 2022Article
- Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia.Expert review of clinical immunology · 2020Article
- The amount of cytokine-release defines different shades of Sars-Cov2 infection.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2020Review
- Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation.Bone marrow transplantation · 2020Article
- Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.Drugs in context · 2019Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29808004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.